Intraperitoneal Meropenem for Polymicrobial Peritoneal Dialysis-Related Peritonitis
- Resource Type
- Authors
- Lily Jakulj; Anthe Zandvliet; Eric Franssen; Caroline W.H. de Fijter; Fariba Amiri
- Source
- Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 36:572-573
- Subject
- medicine.medical_specialty
medicine.medical_treatment
Peritonitis
030226 pharmacology & pharmacy
Gastroenterology
Meropenem
Peritoneal dialysis
03 medical and health sciences
0302 clinical medicine
Short Reports
Peritoneal Dialysis, Continuous Ambulatory
Pharmacokinetics
Fixed time
Internal medicine
polycyclic compounds
medicine
Humans
Infusions, Parenteral
Aged, 80 and over
business.industry
General Medicine
biochemical phenomena, metabolism, and nutrition
bacterial infections and mycoses
medicine.disease
Drug Resistance, Multiple
Anti-Bacterial Agents
Treatment Outcome
Drug concentration
Nephrology
030220 oncology & carcinogenesis
bacteria
Kidney Failure, Chronic
Female
Thienamycins
Patient Safety
business
Follow-Up Studies
medicine.drug
- Language
- ISSN
- 1718-4304
0896-8608
With the current rise in multiresistant gram-negative bacteria, carbapenems are more frequently used. Surprisingly, limited data exist on the pharmacokinetics of meropenem in peritoneal dialysis (PD)-related peritonitis. We report on the pharmacokinetics of repeated intraperitoneal (IP) meropenem during 21 days as treatment for polymicrobial multiresistent PD-related peritonitis. Our current report supports daily doses of 125 mg/L intraperitoneal meropenem in all bags as an effective and safe modality in the treatment of PD-associated peritonitis with multiresistant microorganisms. No signs of over- or underdosing were found based on serial drug concentration measurements at fixed time points up to 21 days.